Xenon(XENE)

Search documents
Xenon(XENE) - 2019 Q1 - Earnings Call Transcript
2019-05-12 15:59
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2019 Earnings Conference Call May 7, 2019 4:30 PM ET Company Participants Jodi Regts - VP, Corporate Affairs and IR Simon Pimstone - CEO Ian Mortimer - President and CFO Conference Call Participants Paul Matteis - Stifel David Martin - Bloom Burton Operator Good day, ladies and gentlemen, and welcome to the Q1 2019 Xenon Pharmaceuticals Inc. Earnings Conference Call. [Operator Instructions]. As a reminder, this conference call is being recorded. I would now like t ...
Xenon(XENE) - 2019 Q1 - Quarterly Report
2019-05-07 20:45
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON PHARMACEUTICALS INC. Indicate by check mark whether the registrant (1) has filed all reports required to be filed b ...
Xenon(XENE) - 2018 Q4 - Earnings Call Transcript
2019-03-07 03:25
Xenon Pharmaceuticals (NASDAQ:XENE) Q4 2018 Results Earnings Conference Call March 6, 2019 4:30 PM ET Company Participants Jodi Regts - VP, Corporate Affairs and IR Simon Pimstone - CEO Ian Mortimer - President and CFO Conference Call Participants Stephen Willey - Stifel Maurice Raycroft - Jefferies Operator Good day, ladies and gentlemen, and welcome to the Fourth Quarter 2018 Xenon Pharmaceuticals Incorporated Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call i ...
Xenon(XENE) - 2018 Q4 - Annual Report
2019-03-06 21:56
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36687 XENON PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation ...